Abcam, ab244570, Anti-CD45RC antibody [MRC OX-22] - BSA and Azide free

Size: 100µg
Mouse Monoclonal CD45 antibody. Carrier free. Suitable for IHC-Fr, IHC-P, Flow Cyt and reacts with Rat, Human samples. Cited in 1 publication.
Key facts
Host species:Mouse,
Clonality:Monoclonal,
Clone number:MRC OX-22,
Isotype:IgG1,
Light chain type:kappa,
Carrier free:Yes,
Reacts with:Rat, Human,
Applications:Flow Cyt, IHC-Fr, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab244570 is the carrier-free version of
ab33945
Want a custom formulation?
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification, Storage buffer-Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Aliquoting information-Upon delivery aliquot, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CD45RC also known as PTPRC isoform 14125 or CD45 plays an essential mechanical role as a protein tyrosine phosphatase. This approximately 180-240 kDa transmembrane protein modulates antigen receptor signaling in lymphocytes. CD45RC is expressed on various immune cells including T cells B cells and natural killer cells with expression levels varying between subsets of these cells. The CD45RC isoform arises from alternative splicing leading to different molecular forms that can affect immune cell signaling.
Biological function summary
CD45RC impacts cell signaling by regulating the threshold of activation in T and B cells. It is a member of the receptor-type protein tyrosine phosphatase family and functions to maintain immune homeostasis. CD45RC does not typically function alone; it interacts with other cell surface molecules to facilitate signal transduction. By dephosphorylating specific kinases it fine-tunes the immune response preventing overreaction and facilitating a rapid appropriate response to antigens.
Pathways
CD45RC modulates pathways involved in lymphocyte activation. One key pathway is the T-cell receptor signaling pathway where it controls the activity of Src family kinases which play a significant part in the early activation of T cells. Another important pathway is the B-cell receptor signaling pathway. CD45RC's action with the BCR complex ensures precise regulation of B cell responses. Its activity is closely related to proteins such as Lck and Fyn which are involved in the signaling cascades initiated by receptor engagement.
CD45RC has implications in autoimmune diseases and certain leukemias. Its altered expression or function can lead to improper immune system regulation which may contribute to autoimmune conditions like rheumatoid arthritis where an overactive immune response targets the body’s own tissues. In some leukemias aberrant CD45RC expression can affect leukemia progression by modulating leukemia cell signaling and interactions within the bone marrow niche. This relationship of CD45RC with disease-related proteins like Lck highlights its potential as a therapeutic target in conditions of immune dysregulation.